Volume 23 Issue 9
Sep.  2025
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2025  >  23(9): 1516-1521
YI Shihua, ZHANG Qiang, LU Xiuyun, WANG Xinwei, WANG Bing. A cross-sectional study on the relationship between the comprehensive index of systemic inflammation and chronic kidney disease[J]. Chinese Journal of General Practice, 2025, 23(9): 1516-1521. doi: 10.16766/j.cnki.issn.1674-4152.004168
Citation: YI Shihua, ZHANG Qiang, LU Xiuyun, WANG Xinwei, WANG Bing. A cross-sectional study on the relationship between the comprehensive index of systemic inflammation and chronic kidney disease[J]. Chinese Journal of General Practice, 2025, 23(9): 1516-1521. doi: 10.16766/j.cnki.issn.1674-4152.004168
shu

A cross-sectional study on the relationship between the comprehensive index of systemic inflammation and chronic kidney disease

doi: 10.16766/j.cnki.issn.1674-4152.004168
  • 1.

    Department of Nephrology, Heilongjiang Academy of Chinese Medicine, Harbin, Heilongjiang 150036, China

Funds:

 2022212101102

  • Received Date: 2024-12-11
    Available Online: 2025-11-17
    Abstract
  •   Objective  Chronic kidney disease (CKD) is characterized by a progressive decline in renal function, which has a detrimental effect on patients ' quality of life, increases mortality risk, and poses a significant public health burden. The aggregate index of systemic inflammation (AISI), a composite biomarker derived from blood cell counts, has not yet been definitively associated with CKD. This cross-sectional study was conducted with the objective of investigating the association between AISI levels and CKD prevalence in a cohort that is nationally representative.  Methods  A total of 9 557 adults from the NHANES 2009-2018 were analyzed, with 912 (9.54%) meeting CKD diagnostic criteria. The following covariates were included in the study: age, gender, race, education, income, poverty ratio, BMI, smoking, drinking, hypertension, diabetes, metabolic syndrome and biomarkers. Multivariable logistic regression models, adjusted for demographic and clinical confounders, were employed to assess the associations between AISI quartiles and CKD risk. Restricted cubic splines were utilized to evaluate linearity, while the ROC, DCA and calibration assessed the model ' s performance.  Results  Participants with CKD exhibited significantly higher median AISI values compared to non-CKD individuals [251.14 (170.39, 403.65) vs. 236.05 (157.08, 363.51), P=0.004]. Elevated AISI levels were found to be independently associated with increased risk of CKD (OR=1.112, 95% CI: 1.040-1.188, P=0.002). A linear dose-response relationship was observed (P for overall < 0.001; P for nonlinear=0.465), with CKD risk rising markedly above the cohort median AISI (237.30). The final model demonstrated strong predictive accuracy AUC value of 0.737(95% CI: 0.718-0.756, P < 0.001). Subgroup analyses further suggested gender-specific modifications of the association between the AISI and CKD.  Conclusion  As a composite inflammatory biomarker, AISI has been demonstrated to exhibit a dose-dependent association with the risk of CKD, particularly at elevated levels. These findings lend support to the hypothesis that the test has the potential utility for population-level CKD risk stratification and for the early identification of high-risk individuals.

     

    • FullText(HTML)
  • loading
    • References(37)
  • [1]
    DEN HARTOGH D J, TSIANI E. Health benefits of resveratrol in kidney disease: evidence from in vitro and in vivo studies[J]. Nutrients, 2019, 11(7): 1624. DOI: 10.3390/nu11071624.
    [2]
    YAMAMOTO H, ICHIKAWA Y, HIRANO S I, et al. Molecular hydrogen as a novel protective agent against pre-symptomatic diseases[J]. Int J Mol Sci, 2021, 22(13): 7211. DOI: 10.3390/ijms22137211.
    [3]
    KANDURI S R, VELEZ J C Q. Kidney dysfunction in the setting of liver failure: core curriculum 2024[J]. Am J Kidney Dis, 2024, 83(3): 386-401.
    [4]
    GALLO-BERNAL S, PATINO-JARAMILLO N, CALIXTO C A, et al. Nephrogenic systemic fibrosis in patients with chronic kidney disease after the use of gadolinium-based contrast agents: a review for the cardiovascular imager[J]. Diagnostics(Basel), 2022, 12(8): 1816. DOI: 10.3390/diagnostics12081816.
    [5]
    GOODBRED A J, LANGAN R C. Chronic kidney disease: prevention, diagnosis, and treatment[J]. Am Fam Physician, 2023, 108(6): 554-561.
    [6]
    范晶, 黄冠文, 包继文, 等. IgA肾病预后相关危险因素分析[J]. 中华全科医学, 2022, 20(5): 731-734, 755. doi: 10.16766/j.cnki.issn.1674-4152.002441

    FAN J, HUANG G W, BAO J W, et al. Analysis of risk factors for the prognosis of IgA nephropathy[J]. Chinese Journal of General Practice, 2022, 20(5): 731-734, 755. doi: 10.16766/j.cnki.issn.1674-4152.002441
    [7]
    SATARUG S, GOBE G C, VESEY D A. Multiple targets of toxicity in environmental exposure to low-dose cadmium[J]. Toxics, 2022, 10(8): 472. DOI: 10.3390/toxics10080472.
    [8]
    WANG B, LI Z S, MAO L F, et al. Hydrogen: a novel treatment strategy in kidney disease[J]. Kidney Dis(Basel), 2022, 8(2): 126-136.
    [9]
    ARIENTI C, LAZZARINI S G, POLLINI E, et al. Effectiveness of rehabilitation interventions in adults with multi-organ dysfunction syndrome: a rapid review[J]. J Rehabil Med, 2021, 53(8): jrm00221. DOI: 10.2340/16501977-2846.
    [10]
    YIN X S, ZOU J M, YANG J. The association between the aggregate index of systemic inflammation and risk of rheumatoid arthritis: retrospective analysis of NHANES 1999-2018[J]. Front Med(Lausanne), 2024, 11: 1446160. DOI: 10.3389/fmed.2024.1446160.
    [11]
    XIU J M, LIN X Q, CHEN Q S, et al. The aggregate index of systemic inflammation (AISI): a novel predictor for hypertension[J]. Front Cardiovasc Med, 2023, 10: 1163900. DOI: 10.3389/fcvm.2023.1163900.
    [12]
    TARLE M, RAGUŽ M, LUK$\bar{\mathtt{S}}$IĆ I. A comparative study of the aggregate index of systemic inflammation (AISI) and c-reactive protein (CRP) in predicting odontogenic abscesses severity: a novel approach to assessing immunoinflammatory response[J]. Diagnostics(Basel), 2024, 14(19): 2163. DOI: 10.3390/diagnostics14192163.
    [13]
    CAO C, LI C Y, LI X T, et al. Association of systemic immune-inflammation index (SII) and aggregate index of systemic inflammation (AISI) with thyroid nodules in patients with type 2 diabetes mellitus: a retrospective study[J]. BMC Endocr Disord, 2023, 23(1): 251. DOI: 10.1186/s12902-023-01509-w.
    [14]
    JIANG Y, LUO B L, LU W, et al. Association between the aggregate index of systemic inflammation and clinical outcomes in patients with acute myocardial infarction: a retrospective study[J]. J Inflamm Res, 2024, 17: 7057-7067. doi: 10.2147/JIR.S481515
    [15]
    QIU S H, JIANG Q, LI Y. The association between pan-immune-inflammation value and chronic obstructive pulmonary disease: data from NHANES 1999-2018[J]. Front Physiol, 2024, 15: 1440264. DOI: 10.3389/fphys.2024.1440264.
    [16]
    XU J P, PENG X Q, GUO L H, et al. The associations of the triglyceride-glucose index and its combination with blood pressure on cardiovascular and all-cause mortality in hypertension: a national study[J]. Front Endocrinol(Lausanne), 2024, 15: 1469055. DOI: 10.3389/fendo.2024.1469055.
    [17]
    CAO Y L, LIN J H, HAMMES H P, et al. Flavonoids in treatment of chronic kidney disease[J]. Molecules, 2022, 27(7): 2365. DOI: 10.3390/molecules27072365.
    [18]
    LOUSA I, REIS F, SANTOS-SILVA A, et al. The signaling pathway of TNF receptors: linking animal models of renal disease to human CKD[J]. Int J Mol Sci, 2022, 23(6): 3284. DOI: 10.3390/ijms23063284.
    [19]
    RANGANATHAN N, ANTEYI E. The role of dietary fiber and gut microbiome modulation in progression of chronic kidney disease[J]. Toxins(Basel), 2022, 14(3): 183. DOI: 10.3390/toxins14030183.
    [20]
    MITROFANOVA A, MERSCHER S, FORNONI A. Kidney lipid dysmetabolism and lipid droplet accumulation in chronic kidney disease[J]. Nat Rev Nephrol, 2023, 19(10): 629-645.
    [21]
    DEROUANE F, VAN MARCKE C, BERLIÈRE M, et al. Predictive biomarkers of response to neoadjuvant chemotherapy in breast cancer: current and future perspectives for precision medicine[J]. Cancers(Basel), 2022, 14(16): 3876. DOI: 10.3390/cancers14163876.
    [22]
    GEORGIANOS P I, VAIOS V, ROUMELIOTIS S, et al. Evidence for cardiorenal protection with SGLT-2 inhibitors and GLP-1 receptor agonists in patients with diabetic kidney disease[J]. J Pers Med, 2022, 12(2): 223. DOI: 10.3390/jpm12020223.
    [23]
    YAN Z P, SHAO T T. Chronic inflammation in chronic kidney disease[J]. Nephron, 2024, 148(3): 143-151.
    [24]
    YANAI H, ADACHI H, HAKOSHIMA M, et al. Molecular biological and clinical understanding of the pathophysiology and treatments of hyperuricemia and its association with metabolic syndrome, cardiovascular diseases and chronic kidney disease[J]. Int J Mol Sci, 2021, 22(17): 9221. DOI: 10.3390/ijms22179221.
    [25]
    WU D P, NIE J L, LIN H G, et al. Characteristics and predictors of low-grade renal artery stenosis in female patients with CKD[J]. Clin Exp Hypertens, 2023, 45(1): 2175849. DOI: 10.1080/10641963.2023.2175849.
    [26]
    LIU W W, WENG S W, CAO C H, et al. Association between monocyte-lymphocyte ratio and all-cause and cardiovascular mortality in patients with chronic kidney diseases: a data analysis from national health and nutrition examination survey (NHANES) 2003-2010[J]. Ren Fail, 2024, 46(1): 2352126. DOI: 10.1080/0886022X.2024.2352126.
    [27]
    GUO W C, SONG Y C, SUN Y, et al. Systemic immune-inflammation index is associated with diabetic kidney disease in type 2 diabetes mellitus patients: evidence from NHANES 2011-2018[J]. Front Endocrinol (Lausanne), 2022, 13: 1071465. DOI: 10.3389/fendo.2022.1071465.
    [28]
    CÍFKOVÁ R, STRILCHUK L. Sex differences in hypertension. Do we need a sex-specific guideline?[J]. Front Cardiovasc Med, 2022, 9: 960336. DOI: 10.3389/fcvm.2022.960336.
    [29]
    RIM C H, LEE W J, MUSAEV B, et al. Consortium of republican specialized scientific practical-medical center of oncology and radiology and south korean oncology advisory group. Challenges and suggestions in management of lung and liver cancer in uzbekistan: the second report of the uzbekistan-korea oncology consortium[J]. Int J Environ Res Public Health, 2022, 19(18): 11727. DOI: 10.3390/ijerph191811727.
    [30]
    PONTICELLI C, CITTERIO F. Non-immunologic causes of late death-censored kidney graft failure: a personalized approach[J]. J Pers Med, 2022, 12(8): 1271. DOI: 10.3390/jpm12081271.
    [31]
    HENRIKSEN K J, CHANG A. The importance of nephropathology in kidney cancer[J]. Semin Nephrol, 2020, 40(1): 69-75.
    [32]
    LI Y F, RICARDO S D, SAMUEL C S. Enhancing the therapeutic potential of mesenchymal stromal cell-based therapies with an anti-fibrotic agent for the treatment of chronic kidney disease[J]. Int J Mol Sci, 2022, 23(11): 6035. DOI: 10.3390/ijms23116035.
    [33]
    YAMAMOTO T, ISAKA Y. Pathological mechanisms of kidney disease in ageing[J]. Nat Rev Nephrol, 2024, 20(9): 603-615.
    [34]
    TURKMEN K, OZER H, KUSZTAL M. The relationship of epicardial adipose tissue and cardiovascular disease in chronic kidney disease and hemodialysis patients[J]. J Clin Med, 2022, 11(5): 1308. DOI: 10.3390/jcm11051308.
    [35]
    CHOW E, YANG A, CHUNG C H L, et al. A clinical perspective of the multifaceted mechanism of metformin in diabetes, infections, cognitive dysfunction, and cancer[J]. Pharmaceuticals (Basel), 2022, 15(4): 442. DOI: 10.3390/ph15040442.
    [36]
    WANG B, LI Z L, ZHANG Y L, et al. Hypoxia and chronic kidney disease[J]. EBioMedicine, 2022, 77: 103942. DOI: 10.1016/j.ebiom.2022.103942.
    [37]
    GABBIN B, MERAVIGLIA V, MUMMERY C L, et al. Toward human models of cardiorenal syndrome in vitro[J]. Front Cardiovasc Med, 2022, 9: 889553. DOI: 10.3389/fcvm.2022.889553.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(3)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (19) PDF downloads(2) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return